Evaluation of miRNA-21 and miRNA Let-7 as Prognostic Markers in Patients With Breast Cancer

• Published in: Clinical breast cancer Vol. 18; no. 4; pp. e721 - e726
• Main Authors: Elghoroury, Eman A., ElDine, Hesham G., Kamel, Solaf A., Abdelrahman, Amany H., Mohammed, Asmaa, Kamel, Mahmoud M., Ibrahim, Mona H.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2018
• Subjects: Adult; Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; Breast Neoplasms - blood; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Cancer breast; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs - blood; MicroRNAs - genetics; Middle Aged; miRNA let-7; miRNA-21; Neoplasm Metastasis - genetics; Prognosis; Prognosis; miRNA-21; miRNA let-7; Cancer breast
• ISSN: 1526-8209; 1938-0666
• DOI: 10.1016/j.clbc.2017.11.022

Cancer breast is a challenging health care problem. We studied the circulating levels of miRNA-21 and miRNA let-7 in 3 different groups. miRNA-21 was highly expressed in patients with breast cancer whereas miRNA let-7 expression was markedly reduced and correlated with risk development of metastases in breast cancer cases. miRNA let-7 arises as a prognostic marker for cancer breast. Breast cancer remains one of the top threats to women’s health. The current lack of tumor markers with desirable sensitivity and specificity is a major obstacle toward the future management of breast cancer. Many studies are directed to reveal the diagnostic and prognostic potentials of circulating miRNAs in breast cancer. In this study, we attempt to evaluate the feasibility and clinical utility of circulating miRNA-21 and let-7 as prognostic biomarkers for breast cancer. Real-time quantitative polymerase chain reaction technique was used. Levels of miRNA-21 and let-7 expression were determined in sera from 125 participants representing 3 different groups. With fold-change analysis, the expression of miRNA-21 and let-7 in the decided groups were assessed. Patients with breast cancer showed significantly higher expression of miRNA-21 compared with controls and other participants with benign breast lesions (P < .001). The mean expression levels of serum miRNA-21 was 3.27 ± 2.10-fold in patients with breast cancer. The expression of miRNA let-7 was significantly decreased in patients with breast cancer (2.45 ± 2.20-fold) than the control group and the benign breast lesions group (5.27 ± 3.30-fold and 6.22 ± 4.90-fold, respectively; P < .001). Levels of miRNA let-7 expression negatively correlated with development of metastases in patients with breast cancer (P < .001). Our study establishes the association between altered levels of miRNA let-7 and metastases risk in patients with breast cancer, implying a role of miRNA let-7 in disease progression and prognosis.